瑞舒伐他汀治疗早发心肌梗死效果及安全性观察  

Efficacy and safety of rosuvastatin in the treatment of early-onset myocardial infarction

作　　者：刘志广 Liu Zhi-guang(Department of Cardiovascular Medicine,Anyang People's Hospital,Anyang 455000,Henan,China)

机构地区：[1]安阳市人民医院心血管内科,河南安阳455000

出　　处：《四川生理科学杂志》2025年第4期812-814,933,共4页

摘　　要：目的:探讨早发心肌梗死患者采取瑞舒伐他汀治疗的效果及安全性。方法:选取2022年9月至2024年6月期间本院心血管内科收治的156例早发心肌梗死患者作为研究对象,采用随机数字表法分为阿托伐他汀组和瑞舒伐他汀组,每组各78例。阿托伐他汀组口服阿托伐他汀20 mg治疗,瑞舒伐他汀组口服瑞舒伐他汀10 mg治疗,均治疗3 m后评价疗效和不良反应。同时于治疗前后采用心脏超声仪检测左室舒张末期内径(Left ventricular end diastolic diameter,LVEDD)、左室收缩末期内径(Left ventricular end systolic diameter,LVESD)及左室射血分数(Left ventricular ejection fraction,LVEF)等心功能指标,采用酶联免疫吸附法检测低密度脂蛋白胆固醇(Low-density lipoprotein,LDL-C)、甘油三酰(Triacyl glyceride,TG)、总胆固醇(Total cholesterol,TC)及高密度脂蛋白胆固醇(High density lipoprotein cholesterol,HDL-C)等血脂水平。结果:瑞舒伐他汀组的治疗总有效率显著高于阿托伐他汀组(P<0.05),而不良反应率差异无统计学意义(P>0.05)。治疗后,两组的LVEDD、LVESD指标均显著降低,LVEF指标显著升高,且瑞舒伐他汀组改善幅度均显著大于对照组(P<0.05)。治疗后,两组的LDL-C、TG、TC等指标均降低,HDL-C均升高,且瑞舒伐他汀组的各项血脂水平的改善幅度均显著大于对照组(P<0.05)。结论:瑞舒伐他汀治疗早发心肌梗死效果显著,能提高治疗效果,改善患者血脂情况及心功能,且安全性较高。Objective:To explore the efficacy and safety of rosuvastatin in the treatment of patients with premature myocardial infarction.Methods:A total of 156 patients with premature myocardial infarction admitted to the Department of CardiovascularMedicine of our hospital from September 2022 to June 2024 were selected as the research subjects.They were randomly divided into atorvastatin group and rosuvastatin group using a random number table method,with 78 cases in each group.The atorvastatin group was treated with oral atorvastatin 20 mg,and the rosuvastatin group was treated with oral rosuvastatin 10 mg,both for 3months.Threemonths later,the efficacy and adverse reactions of the two groups were compared,and cardiac function indicators such as left ventricular end diastolic diameter(LVEDD),left ventricular end systolic diameter(LVESD),and left ventricular ejection fraction(LVEF)were measured using cardiac ultrasound before and after treatment.Enzyme-linked immunosorbent assay was used to detect low-density lipoprotein cholesterol(LDL-C),triacylglyceride(TG),total cholesterol(TC),and high density lipoprotein cholesterol(HDL-C)levels.Results:The total effective rate of rosuvastatin group was significantly higher than that of atorvastatin group(P<0.05),while the difference in adverse reaction rate was not statistically significant(P>0.05).After treatment,the LVEDD and LVESD indicators in both groups decreased significantly,while the LVEF indicator increased significantly.The improvement in the rosuvastatin group was significantly greater than that in the control group(P<0.05).After treatment,the LDL-C,TG,TC and other indicators in both groups decreased,while HDL-C increased.The improvement in each blood lipid level in the rosuvastatin group was significantly greater than that in the control group(P<0.05).Conclusion:Rosuvastatin has significant effect on the treatment of early-onset myocardial infarction,which can improve the therapeutic effect,improve the blood lipid profile and cardiac function of patients,and has high s

关 键 词：早发心肌梗死 瑞舒伐他汀 阿托伐他汀 临床疗效 不良反应 

分 类 号：R541.4[医药卫生—心血管疾病]